However, intraoperative radiotherapy as administered in ELIOT may still be an appropriate option for a subset of patients with extremely favorable tumor biology (well-differentiated luminal A cancers < 1 cm in size with Ki-67 < 14%) who experienced a 10-year ipsilateral breast tumor recurrence rate of <1.3% [51]. Here, MKI67 is linked to breast neoplasm.